PolyPid Ltd.PYPD
Price (close)
$5.36
Market cap
$97.6M
P/E
—
Revenue (FY)
—
Net income
-$34.2M
Dividend yield
—
1-year total return
59.1%
Net margin
—
Revenue growth
—
Debt / equity
0.09x
What PolyPid Ltd. does.
company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins. We develop long-acting,
controlled-release medicines that deliver therapy precisely at the site of care, addressing critical unmet medical needs. Our diverse
pipeline spans surgical care, metabolic diseases, and beyond. Our lead product candidate, D-PLEX 100 , pairs our novel proprietary
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$36.9M | -$42.6M | -$39.6M | -$23.9M | -$29.0M | -$34.2M |
| Free cash flow | -$22.4M | -$35.0M | -$36.1M | -$17.4M | -$22.0M | -$28.1M |
More on PYPD.
- PolyPid Ltd. summary
- PolyPid Ltd. financial statements
- PolyPid Ltd. key metrics
- PolyPid Ltd. health scores and style box
- PolyPid Ltd. earnings
- PolyPid Ltd. dividends
- PolyPid Ltd. valuation
- PolyPid Ltd. ownership and insiders
- PolyPid Ltd. peers
Figures from PolyPid Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.